CereAAV

CereAAV is a novel, genetically engineered adeno-associated virus (AAV) gene therapy vector developed by Takara Bio Inc. It is an AAV2-based serotype optimized through proprietary screening technology to exhibit enhanced tropism for brain and retinal tissues. The vector is specifically designed to penetrate the blood-brain barrier, allowing for the delivery of therapeutic genes to target cells in the central nervous system and the eye via intravenous or intravitreal injection. In preclinical studies, CereAAV demonstrated significantly higher transduction efficiency compared to conventional AAV9 vectors, showing a 50-fold increase in mice and a 20-fold increase in non-human primates for brain targeting. It is currently positioned as a platform technology for the development of gene therapies addressing various brain and retinal diseases.

Brand names

CereAAV